Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are…
15 analysts rate CLYM Buy on consensus.
Consensus price target: $27.60 (+161.86% upside from $10.54)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Thomas Stephen Basil director | Sep 15, 2026 | Sale | 100,000 | $1.37M |
| Thomas Stephen Basil director | Feb 26, 2026 | Sale | 16,313 | $114.29K |
| Thomas Stephen Basil director | Feb 25, 2026 | Sale | 33,687 | $235.96K |
| Thomas Stephen Basil director | Feb 13, 2026 | Sale | 10,000 | $58.14K |
| Thomas Stephen Basil director | Feb 12, 2026 | Sale | 90,000 | $470.99K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $0 | — | $-59.85M |
| 2024 | $0 | — | $-73.9M |
| 2023 | $0 | — | $-35.12M |
Stock data for CLYM: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics